Linkage Therapeutics

Neurodegenerative diseases affect tens of millions of people worldwide, with Alzheimer’s disease impacting approximately 50 million individuals globally, Parkinson’s disease affecting 10 million, and Huntington’s disease, though rarer, placing a devastating burden on patients and families. Despite this immense and growing need, current therapies fall short because they do not address the intracellular accumulation of toxic proteins that drives neuronal dysfunction and cell death. There is an urgent need for neuroprotective interventions that can eliminate toxic proteins from within neurons, preserve neuronal function, and slow or prevent disease progression

Neurodegenerative diseases are driven by the accumulation of toxic, aggregation-prone proteins that disrupt cellular health and lead to progressive neuronal loss. Linkage Therapeutics addresses this unmet need by engineering bifunctional intrabodies that both bind pathogenic targets and direct them to controlled proteasomal degradation.

Linkage Therapeutics is advancing a high-value pipeline anchored by validated biology and in vivo data, with preclinical programs in:

Parkinson’s disease and synucleinopathies, achieving potent reduction of α-synuclein aggregates, preservation of dopaminergic neurons, and improved functional outcomes in vivo

Huntington’s disease, targeting mutant huntingtin (mHTT) with selective intrabodies that reduce toxic aggregation and restore proteostasis.

Alzheimer’s disease and primary tauopathies, demonstrating intrabody-mediated reduction of tau pathology and improved cell survival in human brain organoid models

Linkage Therapeutics is led by internationally recognized scientists with deep expertise in neurodegeneration, intrabody engineering, stem cell biology, and translational neuroscience. The leadership team brings a proven track record of advancing novel biological approaches from discovery through preclinical development and toward the clinic.

Our mission is clear, and we aim to be transparent about our science and approach. The FAQs below address common questions about Linkage Therapeutics and our intrabody platform. If you don’t find what you’re looking for, we invite you to contact us.